comparemela.com

Page 15 - Stevene Nissen News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Silence Therapeutics Announces Detailed Results From SLN360 Phase 1 Study in High Lipoprotein(a) Presented in Late Breaker at the American College of Cardiology (ACC 22) Annual Meeting

03.04.2022 - Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical . Seite 1

United kingdomStevene nissenThoracic institute at cleveland clinicChief academic officerThoracic instituteCleveland clinicSilence therapeutics

Experimental siRNA therapy reduces a key driver of heart disease risk by up to 98%

Findings from a new Cleveland Clinic-led phase 1 trial show that an experimental "gene silencing" therapy reduced blood levels of lipoprotein(a), a key driver of heart disease risk, by up to 98%.

United statesUnited kingdomCity ofStevene nissenEli lillyEmily hendersonCleveland clinic coordinating centerAmerican college of cardiologyJournal of the american medical associationClinical researchBristol myers squibbVascular thoracic institute at cleveland clinicNovo nordiskCleveland clinic ledPlacebo controlled double blind dose rangingAmerican college

Silence Therapeutics Announces Detailed Results from SLN360 Phase 1 Study in High Lipoprotein(a) Presented in Late Breaker at ACC22

SLN360 reduced Lp(a) – a key genetic risk factor for heart disease - by up to 98% with reductions of up to 81% persisting at 150 days

United statesUnited kingdomGiles campionStevene nissenThoracic institute at cleveland clinicAmerican college of cardiologyJournal of the american medical associationSilence therapeuticsPlacebo controlled double blind dose rangingLate breaking science sessionAmerican collegeAnnual scientific sessionAmerican medicalChief academic officerThoracic instituteCleveland clinic

Silence Therapeutics plc: Silence Therapeutics Announces Positive Topline Data in SLN360 Phase 1 Single-Ascending Dose Study in Healthy Adults with High Lipoprotein(a)

SLN360, an investigational siRNA to reduce risk of Lp(a)-mediated cardiovascular disease, was safe and well tolerated in the study SLN360 significantly lowered Lp(a) in a dose-dependent manner up

Giles campionMark rotheraMary conwayStevene nissenHansoh pharmaExchange commissionMallinckrodt pharmaceuticalsCorporate communicationsAmerican college of cardiologyConsilium strategic communicationsAmerican collegeAnnual scientific session expoChief medical officerChief executive officerCardiovascular medicineCleveland clinic

Bariatric Surgery Linked to Protection Against Severe COVID-19

Obesity is a 'modifiable risk factor' for severe COVID-19, researchers say

New yorkUnited statesPaulina salminenStevene nissenAmerican society for metabolicUniversity of turkuCleveland clinicAmerican societyBariatric surgeryNew york city

vimarsana © 2020. All Rights Reserved.